Literature DB >> 1089167

Evaluation of a muscle relaxant: dantrolene sodium (Dantrium).

M H Dykes.   

Abstract

Dantrolene sodium (Dantrium) is a skeletal muscle relaxant, unique in that it acts on the muscle itself. It should be considered for use in patients with skeletal muscle spasticity who are in a stable neurological state. After careful adjustment of the dose, a substantial number of such patients will experience one or more of the following benefits: (1) a reduction in pain, (2) an increased ability to make use of residual motor function, (3) a reduction in the level of nursing care required, (4) an increased ability to utilize devices, and (5) an increased ability to participate in rehabilitation. The drug should not be used when reduced spasticity will decrease functional ability. The adverse effects generally are transient; some are the result of central nervous system depression.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1089167

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  11 in total

Review 1.  Clinical pharmacokinetics in patients with spinal cord injuries.

Authors:  J L Segal; S R Brunnemann
Journal:  Clin Pharmacokinet       Date:  1989-08       Impact factor: 6.447

2.  Complications associated with the administration of dantrolene 1987 to 2006: a report from the North American Malignant Hyperthermia Registry of the Malignant Hyperthermia Association of the United States.

Authors:  Barbara W Brandom; Marilyn Green Larach; Min-Shue Alvin Chen; Michael C Young
Journal:  Anesth Analg       Date:  2011-03-03       Impact factor: 5.108

3.  A calcium-dependent protease as a potential therapeutic target for Wolfram syndrome.

Authors:  Simin Lu; Kohsuke Kanekura; Takashi Hara; Jana Mahadevan; Larry D Spears; Christine M Oslowski; Rita Martinez; Mayu Yamazaki-Inoue; Masashi Toyoda; Amber Neilson; Patrick Blanner; Cris M Brown; Clay F Semenkovich; Bess A Marshall; Tamara Hershey; Akihiro Umezawa; Peter A Greer; Fumihiko Urano
Journal:  Proc Natl Acad Sci U S A       Date:  2014-11-24       Impact factor: 11.205

4.  Effect of dantrolene on KCl- or NMDA-induced intracellular Ca2+ changes and spontaneous Ca2+ oscillation in cultured rat frontal cortical neurons.

Authors:  T Hayashi; A Kagaya; M Takebayashi; T Oyamada; M Inagaki; Y Tawara; N Yokota; J Horiguchi; T P Su; S Yamawaki
Journal:  J Neural Transm (Vienna)       Date:  1997       Impact factor: 3.575

Review 5.  Dantrolene sodium: a review of its pharmacological properties and therapeutic efficacy in spasticity.

Authors:  R M Pinder; R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1977-01       Impact factor: 9.546

Review 6.  Dantrolene. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in malignant hyperthermia, the neuroleptic malignant syndrome and an update of its use in muscle spasticity.

Authors:  A Ward; M O Chaffman; E M Sorkin
Journal:  Drugs       Date:  1986-08       Impact factor: 9.546

7.  A comparison of the effects of sodium thiocyanate and dantrolene sodium on a mammalian isolated skeletal muscle.

Authors:  R F Moulds
Journal:  Br J Pharmacol       Date:  1977-01       Impact factor: 8.739

8.  Successful use of dantrolene sodium in human malignant hyperthermia syndrome: a case report.

Authors:  C M Friesen; J B Brodsky; M F Dillingham
Journal:  Can Anaesth Soc J       Date:  1979-07

Review 9.  Dantrolene: mechanisms of neuroprotection and possible clinical applications in the neurointensive care unit.

Authors:  Susanne Muehlschlegel; John R Sims
Journal:  Neurocrit Care       Date:  2008-08-12       Impact factor: 3.532

Review 10.  The cytoprotective effects of dantrolene: a ryanodine receptor antagonist.

Authors:  Saadet Inan; Huafeng Wei
Journal:  Anesth Analg       Date:  2010-09-22       Impact factor: 6.627

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.